After coming up short in COVID, Valneva focuses on chikungunya vaccine launch
After striking out in an attempt to create a niche for its COVID-19 vaccine, Valneva is taking its swings at what it does best—developing, manufacturing and commercializing vaccines for a variety of infectious diseases with unmet needs. Previously at the …